Cargando…

Fibroblast growth factor receptor type 4 as a potential therapeutic target in clear cell renal cell carcinoma

BACKGROUND: Several clear cell renal cell carcinoma (ccRCC) cases harbour fibroblast growth factor receptor 4 (FGFR4) gene copy number (CN) gains. In this study, we investigated the functional contribution of FGFR4 CN amplification in ccRCC. METHODS: The correlation between FGFR4 CN determined via r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Narisawa, Takafumi, Naito, Sei, Ito, Hiromi, Ichiyanagi, Osamu, Sakurai, Toshihiko, Kato, Tomoyuki, Tsuchiya, Norihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942348/ https://www.ncbi.nlm.nih.gov/pubmed/36803783 http://dx.doi.org/10.1186/s12885-023-10638-3

Ejemplares similares

Effect of Extracellular Signal-Regulated Protein Kinase 5 Inhibition in Clear Cell Renal Cell Carcinoma
por: Kanno, Hidenori, et al.
Publicado: (2022)

Impact of eIF4E phosphorylation at Ser209 via MNK2a on tumour recurrence after curative surgery in localized clear cell renal cell carcinoma
por: Ichiyanagi, Osamu, et al.
Publicado: (2019)

Hemoglobin β Expression Is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma
por: Kurota, Yuta, et al.
Publicado: (2023)

GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition
por: Ito, Hiromi, et al.
Publicado: (2016)

Initial Myeloid Cell Status Is Associated with Clinical Outcomes of Renal Cell Carcinoma
por: Sabrina, Saima, et al.
Publicado: (2023)

Expression of total and phospho 4EBP1 in metastatic and non-metastatic renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2019)

Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2019)

Living kidney transplantation without perioperative anticoagulation therapy for a patient with heparin‐induced thrombocytopenia
por: Nishida, Hayato, et al.
Publicado: (2020)

Expression of Extracellular Signal-regulated Kinase 5 and Ankyrin Repeat Domain 1 in Composite Pheochromocytoma and Ganglioneuroblastoma Detected Incidentally in the Adult Adrenal Gland
por: Suenaga, Shinta, et al.
Publicado: (2016)

Clinical relevance of seasonal changes in the prevalence of ureterolithiasis in the diagnosis of renal colic
por: Fukuhara, Hiroki, et al.
Publicado: (2016)

Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients
por: Takai, Satoshi, et al.
Publicado: (2022)

A GRIA2 and PAX8-positive renal solitary fibrous tumor with NAB2-STAT6 gene fusion
por: Ichiyanagi, Osamu, et al.
Publicado: (2015)

Primary mesenchymal chondrosarcoma of the kidney without HEY1-NCOA2 and IRF2BP2-CDX1 fusion: A case report and review
por: Yamagishi, Atsushi, et al.
Publicado: (2020)

Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kurokawa, Masayuki, et al.
Publicado: (2023)

Body composition changes following chemotherapy for testicular germ cell tumor: obesity is the long-term problem
por: Takai, Yuki, et al.
Publicado: (2021)

Intracellular Major Histocompatibility Complex Class II and C-X-C Motif Chemokine Ligand 10-Expressing Neutrophils Indicate the State of Anti-Tumor Activity Induced by Bacillus Calmette–Guérin
por: Takeda, Yuji, et al.
Publicado: (2023)

Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Renal Cell Carcinoma
por: Sato, Kazunari, et al.
Publicado: (1999)

A durable complete response resulting from treatment with nivolumab plus ipilimumab for metastatic collecting duct carcinoma of the kidney
por: Funajima, Keisuke, et al.
Publicado: (2023)

Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma
por: Tsuchiya, Norihiko, et al.
Publicado: (2014)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021)

Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective study
por: Kato, Renpei, et al.
Publicado: (2022)

Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi‑institutional retrospective study
por: Kato, Renpei, et al.
Publicado: (2023)

Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study
por: Sobu, Ryuta, et al.
Publicado: (2022)

GPI-80 Augments NF-κB Activation in Tumor Cells
por: Takeda, Yuji, et al.
Publicado: (2021)

The Extracellular Matrix Environment of Clear Cell Renal Cell Carcinoma Determines Cancer Associated Fibroblast Growth
por: Bond, Kyle H., et al.
Publicado: (2021)

CCL2 as a potential therapeutic target for clear cell renal cell carcinoma
por: Arakaki, Ryuichiro, et al.
Publicado: (2016)

Modeling Clear Cell Renal Cell Carcinoma and Therapeutic Implications
por: Wolf, Melissa M., et al.
Publicado: (2020)

ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma
por: Seidel, Philipp, et al.
Publicado: (2022)

The role and therapeutic significance of the anoikis pathway in renal clear cell carcinoma
por: Wang, Jin, et al.
Publicado: (2022)

The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases
por: Errarte, Peio, et al.
Publicado: (2016)

Successful pembrolizumab treatment in a patient with metastatic urothelial carcinoma and underlying overlap syndrome involving systemic sclerosis and systemic lupus erythematosus
por: Kurokawa, Masayuki, et al.
Publicado: (2020)

GSDMs are potential therapeutic targets and prognostic biomarkers in clear cell renal cell carcinoma
por: Yao, Lei, et al.
Publicado: (2022)

Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K., et al.
Publicado: (2022)

Detection of specific gene rearrangements by fluorescence in situ hybridization in 16 cases of clear cell sarcoma of soft tissue and 6 cases of clear cell sarcoma-like gastrointestinal tumor
por: Segawa, Keiko, et al.
Publicado: (2018)

BACH1 promotes clear cell renal cell carcinoma progression by upregulating oxidative stress‐related tumorigenicity
por: Takemoto, Kenshiro, et al.
Publicado: (2022)

Promising Epigenetic Biomarkers Associated With Cancer-Associated-Fibroblasts for Progression of Kidney Renal Clear Cell Carcinoma
por: You, Yongke, et al.
Publicado: (2021)

Effects of salivary protein flow and indigenous microorganisms on initial colonization of Candida albicans in an in vivo model
por: Kanaguchi, Norihiko, et al.
Publicado: (2012)

Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma
por: Xu, Kevin Y, et al.
Publicado: (2015)

Clear Cell Adenocarcinoma of the Ureter Similar to Clear Cell Renal Cell Carcinoma Histology
por: Watanabe, Kazuhiro, et al.
Publicado: (2021)

PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma
por: Wang, Jianfeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o1g4tpc63k9n7fftcb0lfdegqd